Effects of S‑adenosyl‑L‑methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms

Mosca,Laura; Minopoli,Michele; Pagano,Martina; Vitiello,Francesca; Carriero,Maria   Vincenza; Cacciapuoti,Giovanna; Porcelli,Marina

doi:10.3892/ijo.2020.5011

Effects of S‑adenosyl‑L‑methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms

Authors:
- Laura Mosca
- Michele Minopoli
- Martina Pagano
- Francesca Vitiello
- Maria Vincenza Carriero
- Giovanna Cacciapuoti
- Marina Porcelli
View Affiliations

Affiliations: Dipartimento di Medicina di Precisione, Università della Campania 'Luigi Vanvitelli', I‑80138 Napoli, Italy, Unità Progressione Neoplastica, Istituto Nazionale Tumori‑IRCCS 'Fondazione G. Pascale', I‑80131 Napoli, Italy
Published online on: March 12, 2020 https://doi.org/10.3892/ijo.2020.5011
Pages: 1212-1224
Copyright: © Mosca et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

S‑Adenosyl‑L‑methionine (AdoMet) is the principal methyl donor in transmethylation reactions fundamental to sustaining epigenetic modifications. Over the past decade, AdoMet has been extensively investigated for its anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in several types of human cancer. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide, and is an aggressive type of cancer that is associated with a high recurrence rate, metastasis and poor treatment outcomes. The present study demonstrates, for the first time, to the best of our knowledge, that AdoMet induces cell cycle arrest and inhibits the migratory and invasive ability of two different HNSCC cell lines, oral Cal‑33 and laryngeal JHU‑SCC‑011 cells. In both cell lines, AdoMet attenuated cell cycle progression, decreased the protein level of several cyclins and downregulated the expression of p21 cell cycle inhibitor. Moreover, AdoMet was able to inhibit Cal‑33 and JHU‑SCC‑011 cell migration in a dose‑dependent manner after 24 and 48 h, respectively, and also induced a significant reduction in the cell invasive ability, as demonstrated by Matrigel invasion assay monitored by the xCELLigence RTCA system. Western blot analysis of several migration and invasion markers confirmed the inhibitory effects exerted by AdoMet on these processes and highlighted AKT, β‑catenin and small mothers against decapentaplegic (SMAD) as the main signaling pathways modulated by AdoMet. The present study also demonstrated that the combination of AdoMet and cisplatin synergistically inhibited HNSCC cell migration. Taken together, these findings demonstrate that the physiological compound, AdoMet, affects the motility and extracellular matrix invasive capability in HNSCC. Thus, AdoMet may prove to be a good candidate for future drug development against metastatic cancer.

View Figures

View References

1	Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG and Coman WB: Head and neck cancer: Past, present and future. Expert Rev Anticancer Ther. 6:1111–1118. 2006. View Article : Google Scholar : PubMed/NCBI
2	Marur S and Forastiere AA: Head and neck squamous cell carcinoma: Update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 91:386–396. 2016. View Article : Google Scholar : PubMed/NCBI
3	Kumar M, Nanavati R, Modi TG and Dobariya C: Oral cancer: Etiology and risk factors: A review. J Cancer Res Ther. 12:458–463. 2016. View Article : Google Scholar : PubMed/NCBI
4	Kulkarni P and Saxena U: Head and neck cancers, the neglected malignancies: Present and future treatment strategies. Expert Opin Ther Targets. 18:351–354. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lu SC: S-Adenosylmethionine. Int J Biochem Cell Biol. 32:391–395. 2000. View Article : Google Scholar : PubMed/NCBI
6	Mato MJ, Cor rales FJ, Lu SC and Avila MA: S-Adenosylmethionine: A control switch that regulates liver function. FASEB J. 16:15–26. 2002. View Article : Google Scholar : PubMed/NCBI
7	Fontecave M, Atta M and Mulliez E: S-Adenosylmethionine: Nothing goes to waste. Trends Biochem Sci. 29:243–249. 2004. View Article : Google Scholar : PubMed/NCBI
8	Ansorena E, García-Trevijano ER, Martínez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iraburu M, Lu SC and Avila MA: S-Adenosylmethionine and methylthioadenosine are anti-apoptotic in cultured rat hepatocytes but pro-apoptotic in human hepatoma cells. Hepatol. 35:274–280. 2002. View Article : Google Scholar
9	Lu SC and Mato JM: S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol. 23(Suppl 1): S73–S77. 2008. View Article : Google Scholar : PubMed/NCBI
10	Martínez-López N, Varela-Rey M, Ariz U, Embade N, Vazquez-Chantada M, Fernandez-Ramos D, Gomez-Santos L, Lu SC, Mato JM and Martinez-Chantar ML: S-Adenosylmethionine and proliferation: New pathways, new targets. Biochem Soc Trans. 36:848–852. 2008. View Article : Google Scholar : PubMed/NCBI
11	Ilisso CP, Sapio L, Delle Cave D, Illiano M, Spina A, Cacciapuoti G, Naviglio S and Porcelli M: S-Adenosylmethionine affects ERK1/2 and Stat3 pathways and induces apoptosis in osteosarcoma cells. J Cell Physiol. 231:428–435. 2016. View Article : Google Scholar
12	Cave DD, Desiderio V, Mosca L, Ilisso CP, Mele L, Caraglia M, Cacciapuoti G and Porcelli M: S-Adenosylmethionine-mediated apoptosis is potentiated by autophagy inhibition induced by chloroquine in human breast cancer cells. J Cell Physiol. 233:1370–1383. 2018. View Article : Google Scholar
13	Mosca L, Pagano M, Ilisso CP, Cave DD, Desiderio V, Mele L, Caraglia M, Cacciapuoti G and Porcelli M: AdoMet triggers apoptosis in head and neck squamous cancer by inducing ER stress and potentiates cell sensitivity to cisplatin. J Cell Physiol. 234:13277–13291. 2019. View Article : Google Scholar
14	Steeg PS: Tumour metastasis: Mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
15	Braakhuis BJ, Senft A, de Bree R, de Vries J, Ylstra B, Cloos J, Kuik DJ, Leemans CR and Brakenhoff RH: Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. J Clin Pathol. 59:1254–1260. 2006. View Article : Google Scholar : PubMed/NCBI
16	Pakneshan P, Szyf M, Farias-Eisner R and Rabbani SA: Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem. 279:31735–31744. 2004. View Article : Google Scholar : PubMed/NCBI
17	Shukeir N, Pakneshan P, Chen G, Szyf M and Rabbani SA: Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66:9202–9210. 2006. View Article : Google Scholar : PubMed/NCBI
18	Chik F, Machnes Z and Szyf M: Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosylmethionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Carcinogenesis. 35:138–144. 2014. View Article : Google Scholar
19	Hussain Z, Khan MI, Shahid M and Almajhdi FN: S-adenosylmethionine, a methyl donor, up regulates tissue inhibitor of metalloproteinase-2 in colorectal cancer. Genet Mol Res. 12:1106–1118. 2013. View Article : Google Scholar : PubMed/NCBI
20	Parashar S, Cheishvili D, Arakelian A, Hussain Z, Tanvir I, Khan HA, Szyf M and Rabbani SA: S-Adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: Therapeutic and diagnostic clinical applications. Cancer Med. 4:732–744. 2015. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Bi T, Liu L, Gao Q, Shen G and Qin L: S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Naunyn Schmiedebergs Arch Pharmacol. 392:615–622. 2019. View Article : Google Scholar : PubMed/NCBI
22	Sun L, Zhang J, Yang Q, Si Y, Liu Y, Wang Q, Han F and Huang Z: Synergistic Effects of SAM and selenium compounds on proliferation, migration and adhesion of HeLa cells. Anticancer Res. 37:4433–4441. 2017.PubMed/NCBI
23	Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51. 1995. View Article : Google Scholar : PubMed/NCBI
24	Bradford MM: Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
25	Fratangelo F, Camerlingo R, Carriero MV, Pirozzi G, Palmieri G, Gentilcore G, Ragone C, Minopoli M, Ascierto PA and Motti ML: Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. Int J Oncol. 53:1149–1159. 2018.PubMed/NCBI
26	Ingangi V, Bifulco K, Yousif AM, Ragone C, Motti ML, Rea D, Minopoli M, Botti G, Scognamiglio G, Fazioli F, et al: The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chon-drosarcoma cells. Oncotarget. 7:54474–54487. 2016. View Article : Google Scholar : PubMed/NCBI
27	Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005. View Article : Google Scholar : PubMed/NCBI
28	Gutierrez GJ, Tsuji T, Cross JV, Davis RJ, Templeton DJ, Jiang W and Ronai ZA: JNK-mediated phosphorylation of Cdc25C regulates cell cycle entry and G(2)/M DNA damage checkpoint. J Biol Chem. 285:14217–14228. 2010. View Article : Google Scholar : PubMed/NCBI
29	Kanwal R and Gupta S: Epigenetic modifications in cancer. Clin Genet. 81:303–311. 2012. View Article : Google Scholar
30	Carriero MV and Stoppelli MP: The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 17:1944–1961. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
32	Kidacki M, Lehman HL, Warrick JI and Stairs DB: Signaling pathways supporting tumor invasion in head and neck squamous cell carcinoma. J Clin Exp Pathol. 5:2272014.
33	Silva BS, Yamamoto FP, Pontes FS, Cury SE, Fonseca FP, Pontes HA and Pinto-Júnior DD: TWIST and p-Akt immune expression in normal oral epithelium, oral dysplasia and in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 17:e29–e34. 2012. View Article : Google Scholar
34	Zuo JH, Zhu W, Li MY, Li XH, Yi H, Zeng GQ, Wan XX, He QY, Li JH, Qu JQ, et al: Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem. 112:2508–2517. 2011. View Article : Google Scholar : PubMed/NCBI
35	Sheng S, Qiao M and Pardee AB: Metastasis and AKT activation. J Cell Physiol. 218:451–454. 2009. View Article : Google Scholar
36	Marcucci F, Stassi G and De Maria R: Epithelial-mesenchymal transition: A new target in anticancer drug discovery. Nat Rev Drug Discov. 15:311–325. 2016. View Article : Google Scholar : PubMed/NCBI
37	Xu W, Yang Z and Lu N: A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 9:317–324. 2015. View Article : Google Scholar : PubMed/NCBI
38	Feng XH and Derynck R: Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol. 21:659–693. 2005. View Article : Google Scholar
39	Suriyamurthy S, Baker D, Ten Dijke P and Iyengar PV: Epigenetic reprogramming of TGF-β signaling in breast cancer. Cancers (Basel). 11. pp. E7262019, View Article : Google Scholar
40	Guo W, Flanagan J, Jasuja R, Kirkland J, Jiang L and Bhasin S: The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathway. J Biol Chem. 283:9136–9145. 2008. View Article : Google Scholar : PubMed/NCBI
41	Minoo P and Li C: Cross-talk between transforming growth factor-beta and Wingless/Int pathways in lung development and disease. Int J Biochem Cell Biol. 42:809–812. 2010. View Article : Google Scholar : PubMed/NCBI
42	Liu J, Wang Y, Pan Q, Su Y, Zhang Z, Han J, Zhu X, Tang C and Hu D: Wnt/β-catenin pathway forms a negative feedback loop during TGF-β1 induced human normal skin fibroblast-to-myofi-broblast transition. J Dermatol Sci. 65:38–49. 2012. View Article : Google Scholar
43	Boldbaatar A, Lee S, Han S, Jeong AL, Ka HI, Buyanravjikh S, Lee JH, Lim JS, Lee MS and Yang Y: Eupatolide inhibits the TGF-β1-induced migration of breast cancer cells via downregu-lation of SMAD3 phosphorylation and transcriptional repression of ALK5. Oncol Lett. 14:6031–6039. 2017.PubMed/NCBI
44	Jin Y, Chen W, Yang H, Yan Z, Lai Z, Feng J, Peng J and Lin J: Scutellaria barbata D. Don inhibits migration and invasion of colorectal cancer cells via suppression of PI3K/AKT and TGF-β/Smad signaling pathways. Exp Ther Med. 14:5527–5534. 2017.PubMed/NCBI
45	Cai W, Yu D, Fan J, Liang X, Jin H, Liu C, Zhu M, Shen T, Zhang R, Hu W, et al: Quercetin inhibits transforming growth factor β1-induced epithelial-mesenchymal transition in human retinal pigment epithelial cells via the Smad pathway. Drug Des Devel Ther. 12:4149–4161. 2018. View Article : Google Scholar :
46	Fustè NP, Castelblanco E, Felip I, Santacana M, Fernández-Hernández R, Gatius S, Pedraza N, Pallarés J, Cemeli T, Valls J, et al: Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer. Oncotarget. 7:26979–26991. 2016. View Article : Google Scholar : PubMed/NCBI
47	Georgakilas AG, Martin OA and Bonner WM: p21: A two-faced genome guardian. Trends Mol Med. 23:310–319. 2017. View Article : Google Scholar : PubMed/NCBI
48	Jung YS, Qian Y and Chen X: Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 22:1003–1012. 2010. View Article : Google Scholar : PubMed/NCBI
49	Dai M, Al-Odaini AA, Arakelian A, Rabbani SA, Ali S and Lebrun JJ: A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion. Breast Cancer Res. 14:R1272012. View Article : Google Scholar
50	Dai M, Al-Odaini AA, Fils-Aimé N, Villatoro MA, Guo J, Arakelian A, Rabbani SA, Ali S and Lebrun JJ: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res. 15:R492013. View Article : Google Scholar
51	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
52	Yin P, Song G and Jiang Z: Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1. Cancer Chemother Pharmacol. 81:863–872. 2018. View Article : Google Scholar : PubMed/NCBI
53	Luo J, Li YN, Wang F, Zhang WM and Geng X: S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biol Sci. 6:784–795. 2010. View Article : Google Scholar : PubMed/NCBI
54	Lu SC and Mato JM: S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 92:1515–1542. 2012. View Article : Google Scholar : PubMed/NCBI
55	Mahmood N, Cheishvili D, Arakelian A, Tanvir I, Khan HA, Pépin AS, Szyf M and Rabbani SA: Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications. Oncotarget. 9:5169–5183. 2018. View Article : Google Scholar : PubMed/NCBI